As published by NYSE on LinkedIn here: “Ochre Bio is on a mission to revolutionize liver disease treatment. Co-Founder + CEO Jack O’Meara talks with Judy Khan Shaw about their ‘human first’ approach and how machine learning technology sets them apart in drug development on NYSEFloorTalk.”
LifeLink Ventures is very proud to see Ochre’s recognition and evolution.
You can see the interview on NYSE’s Youtube Chanel here.
